Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketoconazole for EGFR Inhibitor-Induced Rash
NCT03471364Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Sep 2018
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Ketoconazole Cream in EGFR inhibitor-induced acneiform rash (2 arms), sponsored by Mayo Clinic. Primary endpoint: Proportion of patients who report an improvement in skin rash at 4 weeks. Started Sep 2018; status: completed.
02
Drugs
Ketoconazole Cream
03
Conditions
EGFR inhibitor-induced acneiform rash
Beyond the preview
Go deeper on NCT03471364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03471364.